5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells

This study aimed to discover new potential mechanisms of chemotherapy with drugs used in the treatment of luminal androgen receptor (LAR)-type triple-negative breast cancer (TNBC). We examined the microRNA (miRNA) expression profiles of LAR-type TNBC in vitro, and explored the variation in miRNA expression profiles in cells when treated with the chemotherapy drugs capecitabine and ixabepilone. The present study revealed that the expression levels of the three antitumor miRNAs, miR-122a, miR-145 and miR-205, were significantly elevated in MDA-MB-453 LAR-type TNBC tumor cells treated with 5-fluorouracil together with ixabepilone. By contrast, carcinogenic miR-296 miRNA expression significantly declined, and levels of several other miRNAs such as miR-221, miR-210, miR-21 and miR-10b were also altered. The drugs may exert their effects through the regulation of miRNA expression levels, thereby providing a theoretical basis for clinical implementation of miRNA expression profiles as a diagnostic method for the early diagnosis, classification and prognosis of breast cancer.

[1]  Renato Baserga,et al.  microRNA, cell cycle, and human breast cancer. , 2010, The American journal of pathology.

[2]  M. Campone,et al.  Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. , 2012, Breast.

[3]  Bing-he Xu,et al.  Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment , 2010, Cancer Chemotherapy and Pharmacology.

[4]  C. Sotiriou,et al.  Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer , 2011, PloS one.

[5]  Lun Li,et al.  Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer. , 2010, Future oncology.

[6]  E. Perez,et al.  Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.

[7]  Edith A Perez,et al.  MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. , 2011, Trends in molecular medicine.

[8]  F. Su,et al.  Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[9]  M. Sang,et al.  [Effect of microRNA-mediated p65 gene silencing on the proliferation and apoptosis of human breast cancer MDA-MB-231 cells]. , 2011, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[10]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. McGrowder,et al.  Triple negative breast cancer: therapeutic and prognostic implications. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[12]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[13]  E. Perez,et al.  Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies , 2011, Breast Cancer Research and Treatment.

[14]  C. Croce,et al.  MicroRNA-cancer connection: the beginning of a new tale. , 2006, Cancer research.

[15]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[16]  C. Walko,et al.  Capecitabine: a review. , 2005, Clinical therapeutics.

[17]  H. Yamauchi,et al.  Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy , 2011, Breast cancer.

[18]  Baohong Zhang,et al.  5‐fluorouracil drug alters the microrna expression profiles in MCF‐7 breast cancer cells , 2011, Journal of cellular physiology.

[19]  P. Fumoleau,et al.  The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment , 2012, The breast journal.

[20]  R. Sutherland,et al.  MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. , 1994, European journal of cancer.

[21]  Kuo Yao-Lung,et al.  Clinicopathological features of triple-negative breast cancer in Taiwanese women , 2011, International Journal of Clinical Oncology.

[22]  J. Didziapetriene,et al.  Triple negative breast cancer: adjuvant chemotherapy effect on survival. , 2011, Advances in medical sciences.

[23]  A. Armugam,et al.  MicroRNAs as therapeutic targets in human diseases , 2007, Expert opinion on therapeutic targets.

[24]  Maria Kafousi,et al.  MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer , 2011, Cell cycle.

[25]  E. Rakha,et al.  Metastatic triple-negative breast cancer. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[27]  L. Wang,et al.  MicroRNA-mediated breast cancer metastasis: from primary site to distant organs , 2012, Oncogene.

[28]  I. Pogribny,et al.  MicroRNA-mediated drug resistance in breast cancer , 2011, Clinical Epigenetics.

[29]  R. Hellens,et al.  Quantitative stem-loop RT-PCR for detection of microRNAs. , 2011, Methods in molecular biology.

[30]  Li Yang,et al.  Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. , 2011, Molecular medicine reports.

[31]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[32]  H. Liu,et al.  Effect of microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in MDA-MB-231 cells. , 2010, Tumori.

[33]  A. Chan,et al.  Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line , 2011, BMC Cancer.

[34]  S. Eccles,et al.  Breast cancer metastasis: when, where, how? , 2005, The Lancet.

[35]  Matthew J. Ellis,et al.  Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy , 2011, International journal of breast cancer.

[36]  F. Lee,et al.  Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence , 2011, Therapeutic advances in medical oncology.

[37]  Li Xie,et al.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression , 2010, Journal of experimental & clinical cancer research : CR.

[38]  Bing-he Xu,et al.  Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Swain,et al.  Ixabepilone: clinical role in metastatic breast cancer. , 2011, Clinical breast cancer.

[40]  C. Minami,et al.  Management Options in Triple-Negative Breast Cancer , 2011, Breast cancer : basic and clinical research.

[41]  T. Traina,et al.  Triple-Negative Breast Cancer: Adjuvant Therapeutic Options , 2011, Chemotherapy research and practice.

[42]  M. Fornier.  Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. , 2010, Clinical breast cancer.

[43]  M. van Engeland,et al.  Characteristics of triple-negative breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.